Healthcare of Ontario Pension Plan Trust Fund Sells 20,000 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Healthcare of Ontario Pension Plan Trust Fund trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 84.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,700 shares of the biotechnology company’s stock after selling 20,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in United Therapeutics were worth $850,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in United Therapeutics during the 4th quarter valued at $100,519,000. Nordea Investment Management AB increased its position in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after buying an additional 262,222 shares during the period. Avidity Partners Management LP purchased a new position in United Therapeutics during the fourth quarter valued at approximately $52,158,000. LSV Asset Management grew its stake in United Therapeutics by 40.3% during the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock valued at $121,641,000 after acquiring an additional 152,151 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in United Therapeutics by 309.7% during the 4th quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after acquiring an additional 101,419 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total value of $929,124.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $33,551.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $258.09, for a total value of $929,124.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $33,551.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 100,884 shares of company stock worth $29,622,803. 12.50% of the stock is owned by insiders.

United Therapeutics Price Performance

UTHR opened at $336.37 on Friday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $343.98. The company has a market cap of $14.92 billion, a price-to-earnings ratio of 15.90, a price-to-earnings-growth ratio of 1.45 and a beta of 0.55. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $301.73 and a two-hundred day simple moving average of $256.49.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue was up 33.7% on a year-over-year basis. During the same period last year, the company posted $4.86 EPS. Research analysts predict that United Therapeutics Co. will post 24.87 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on UTHR. TD Cowen raised their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. UBS Group lifted their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Wells Fargo & Company lifted their price target on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Finally, Oppenheimer increased their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $330.64.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.